MarketCapExport financials
Prothena Corporation plc (PRTA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Prothena Corporation plc Income Statement 2025-2010 | PRTA
Brief overview of income trends at Prothena Corporation plc
This overview is based on financial performance over the past five years. The revenue attributed to Prothena Corporation plc moved from 853 thousand dollars to 9.7 million dollars between the two endpoints. The cumulative result was +1035.3%, corresponding to roughly 62.6% per year. This pace points to rapid expansion of the business.
The operating result measured by EBITDA moved from −$111 million to −$214 million, or −92.2%. The operating result developed less favorably than sales. The EBITDA share of revenue changed from −13038.7% to −2207.2%. The increased EBITDA share is a positive sign.
The final result was −$111 million initially and −$244 million in the final year. The period ended with a larger loss than it began with.
The market value of the business moved from $891 million to $251 million, or −71.8%. Financial performance is stronger than the share-price trend.
What the figures show
The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on sales growth and higher operating efficiency. Caution is warranted because of a low EBITDA margin, a weaker final result and a weaker market valuation. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Prothena Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
251 M | 801 M | 1.43 B | 2.66 B | 1.53 B | 891 M | 493 M | 465 M | 1.61 B | 1.59 B | 1.18 B | 558 M | 596 M | 88.3 M | - | - |
Shares |
53.8 M | 53.8 M | 53.2 M | 47.4 M | 44.2 M | 39.9 M | 39.9 M | 39.6 M | 37.7 M | 34.4 M | 30.3 M | 24.7 M | 18.6 M | 14.6 M | - | - |
Historical Prices |
4.66 | 14.9 | 26.9 | 56.2 | 34.6 | 22.3 | 10.7 | 13.4 | 33.7 | 58.6 | 31.8 | 26.6 | 36 | 6.17 | - | - |
Net Income |
-244 M | -122 M | -147 M | -117 M | 67 M | -111 M | -77.7 M | -156 M | -153 M | -160 M | -80.6 M | -7.15 M | -41 M | -41.4 M | -29.7 M | - |
Revenue |
9.68 M | 135 M | 91.4 M | 53.9 M | 201 M | 853 K | 814 K | 955 K | 27.5 M | 1.06 M | 1.61 M | 50.9 M | 676 K | 2.66 M | 507 K | - |
Operating Income |
-215 M | -155 M | -191 M | -132 M | 72 M | -113 M | -85.7 M | -159 M | -155 M | -160 M | -79.9 M | -6.65 M | -40.4 M | -41.4 M | -29.2 M | - |
Interest Expense |
-328 K | -185 K | -458 K | -397 K | -96 K | -62 K | 196 K | 48 K | -2.21 M | 15 K | -170 K | 231 K | -225 K | - | - | - |
EBITDA |
-214 M | -154 M | -190 M | -131 M | 73.1 M | -111 M | -78.9 M | -139 M | -152 M | -157 M | -79.1 M | -5.91 M | -39.8 M | -40.9 M | -28.9 M | - |
Operating Expenses |
224 M | 290 M | 282 M | 185 M | 129 M | 114 M | 86.6 M | 144 M | 183 M | 161 M | 81.5 M | 57.5 M | 41.1 M | 44.1 M | - | - |
General and Administrative Expenses |
59.4 M | 67.2 M | 61.8 M | 49.9 M | 46.3 M | 38.7 M | 35.7 M | 42.5 M | 48.2 M | 41.1 M | 23.1 M | 19.1 M | 15.1 M | 9.93 M | 5.58 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Prothena Corporation plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
51.4 M | 52.1 M | 53.7 M | - | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 53.7 M | 53.7 M | 53.6 M | 53.1 M | 52.5 M | 52.1 M | 47 M | 46.8 M | 46.7 M | 46.7 M | 45.6 M | 44.3 M | 40.2 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 39.8 M | 39.8 M | 38.7 M | 38.5 M | 38.3 M | 38.1 M | 35.8 M | 34.8 M | 34.4 M | 34.4 M | 34 M | 31.7 M | 31.4 M | 30.8 M | 27.4 M | 27.4 M | 27.4 M | 22 M | 21.9 M | 21.9 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 14.5 M | 14.5 M | 14.5 M | - | - | - | - |
Net Income |
-16.5 M | -18.6 M | 32.7 M | - | -36.5 M | -126 M | -60.2 M | - | -59 M | 66.9 M | -72.2 M | - | 21.9 M | -54.6 M | -46.9 M | - | -45.8 M | -41.2 M | -36.3 M | - | 109 M | 27.6 M | -36.7 M | -30.7 M | -30.6 M | -26.3 M | -23.6 M | -21.6 M | -19.4 M | -15.8 M | -20.9 M | -22.5 M | -24.6 M | -59.9 M | -48.7 M | -47.8 M | -52.4 M | -17.7 M | -35.4 M | -48.9 M | -43.2 M | -40.4 M | -27.5 M | -24.2 M | -23 M | -18.3 M | -15.2 M | -13.1 M | -13.2 M | 1.29 M | 17.9 M | -11.1 M | -9.69 M | -11.3 M | -8.95 M | -12.2 M | -8.67 M | -9.71 M | -10.8 M | - | - | - | - |
Revenue |
620 K | 1.01 M | 51.1 M | - | 2.42 M | 4.42 M | 2.83 M | - | 970 K | 132 M | 50 K | - | 84.9 M | 4.02 M | 2.17 M | - | 1.52 M | 1.31 M | 1.15 M | - | 139 M | 60.1 M | 160 K | 360 K | 157 K | 195 K | 141 K | 256 K | 205 K | 167 K | 186 K | 194 K | 255 K | 279 K | 227 K | 229 K | 219 K | 26.8 M | 259 K | 171 K | 286 K | 333 K | 265 K | 307 K | 429 K | 278 K | 593 K | 2.01 M | 1.49 M | 15.1 M | 32.2 M | 167 K | 171 K | 167 K | 171 K | 575 K | 944 K | 735 K | 404 K | - | - | - | - |
Operating Income |
-18.8 M | -21.1 M | 30 M | - | -40.2 M | -84.6 M | -65.6 M | - | -66.5 M | 58.4 M | -81.5 M | - | 10.3 M | -66.5 M | -56.3 M | - | -50.3 M | -43.2 M | -37.9 M | - | 109 M | 27.9 M | -32.1 M | - | -30.8 M | -26.7 M | -24.8 M | - | -21 M | -18.5 M | -23 M | - | -24.3 M | -63.1 M | -48.7 M | - | -53.5 M | -18.1 M | -36.3 M | - | -42.7 M | -40.2 M | -27.4 M | - | -22.7 M | -18 M | -15 M | - | -13.1 M | 1.57 M | 18 M | - | -9.57 M | -11.2 M | -8.97 M | - | -8.67 M | -9.71 M | -10.8 M | - | - | - | - |
Interest Expense |
2.32 M | -33 K | 271 K | - | -23 K | -143 K | -140 K | - | -66 K | -51 K | -77 K | - | -15 K | -97 K | -141 K | - | 2 K | -2 K | -70 K | - | -42 K | -61 K | 23 K | - | 11 K | 16 K | -24 K | - | -42 K | 235 K | -17 K | - | -65 K | 410 K | -272 K | - | -683 K | -874 K | -410 K | - | -268 K | -86 K | -207 K | - | -127 K | -87 K | 67 K | - | 172 K | 1 K | -35 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-18.6 M | -20.7 M | 30.2 M | - | -40 M | -84.4 M | -65.4 M | - | -66.3 M | 58.6 M | -81.3 M | - | 10.5 M | -66.3 M | -56.1 M | - | -50.1 M | -43 M | -37.8 M | - | 110 M | 28.5 M | -31.8 M | - | -29.7 M | -26 M | -24.5 M | - | -19.8 M | -17.7 M | -22.6 M | - | -21.9 M | -61.5 M | -47.9 M | - | -51.2 M | -16.6 M | -35.5 M | - | -41.2 M | -39.5 M | -27.2 M | - | -22.1 M | -17.6 M | -14.8 M | - | -12.9 M | 1.77 M | 18.2 M | - | -9.47 M | -11 M | -8.96 M | - | -8.36 M | -9.48 M | -10.7 M | - | - | - | - |
Operating Expenses |
19.4 M | 22.1 M | 21 M | - | 42.7 M | 89 M | 68.4 M | - | 67.5 M | 73.6 M | 81.6 M | - | 74.6 M | 70.5 M | 58.5 M | - | 51.8 M | 44.5 M | 39.1 M | - | 29.9 M | 32.1 M | 32.3 M | 30.7 M | 31 M | 26.9 M | 25 M | 23.5 M | 21.2 M | 18.7 M | 23.1 M | 22.9 M | 24.6 M | 63.3 M | 48.9 M | 47.5 M | 53.8 M | 44.9 M | 36.5 M | 49.4 M | 43 M | 40.5 M | 27.7 M | 24.5 M | 23.1 M | 18.3 M | 15.6 M | 15.1 M | 14.6 M | 13.6 M | 14.2 M | 10.9 M | 9.74 M | 11.4 M | 9.14 M | 12.8 M | 9.61 M | 10.4 M | 11.2 M | - | - | - | - |
General and Administrative Expenses |
10.6 M | 10.9 M | 12.7 M | - | 13.2 M | 15.9 M | 17.6 M | - | 16.8 M | 16.1 M | 17.5 M | - | 16.6 M | 14.5 M | 13.7 M | - | 12 M | 13 M | 11.8 M | - | 12 M | 11 M | 11.1 M | - | 9.4 M | 9.66 M | 9.74 M | - | 8.69 M | 9.08 M | 9.9 M | - | 9.24 M | 11 M | 14.2 M | - | 12.4 M | 10.9 M | 10.8 M | - | 16.1 M | 8.13 M | 7.18 M | - | 5.9 M | 5.52 M | 5.05 M | - | 4.23 M | 4.94 M | 4.87 M | - | 3.39 M | 3.21 M | 3.18 M | - | 2.08 M | 2.43 M | 2.46 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Prothena Corporation plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
$ 291.22 | 1.06 % | $ 515 B |  USA |
 |
22nd Century Group
XXII
|
$ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
$ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
$ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
$ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
$ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
$ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
$ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
$ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
$ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
$ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
$ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
$ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
$ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | USA |
 |
Codexis
CDXS
|
$ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
$ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
$ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
$ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
$ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
- | - | - |  Russia |
 |
CorMedix
CRMD
|
$ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
$ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
$ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
$ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
- | - | - | Russia |
 |
Codiak BioSciences
CDAK
|
- | -55.98 % | $ 2.15 M | USA |